Martin Holst Lange

Dr. Martin Holst Lange holds a medical degree and a PhD in Endocrinology from the University of Copenhagen. With nearly 25 years of experience in the pharmaceutical industry, Dr. Lange has dedicated his career to advancing healthcare through innovative treatments in diabetes and other metabolic disorders.

Joining Novo Nordisk in 2002 as a medical doctor, Dr. Lange has worked on various projects involving growth hormone, GLP-2, and oral anti-diabetics. His career has taken him through several key leadership roles within the company, including a two-year period at Novo Nordisk Inc. in the USA that broadened his perspective on global healthcare challenges.

In January 2018, Dr. Lange became Senior Vice President of Global Development, taking on responsibility for the clinical development of Novo Nordisk’s pipeline. He was promoted to Executive Vice President of Development in March 2021, and in August 2025, he assumed the role of Executive Vice President and Chief Scientific Officer (CSO) following the merger of the Research & Early Development and Development divisions. In these roles, he is responsible for all phase of drug discovery and development with a strong patient-centric approach.

Dr. Lange's leadership has contributed to expanding Novo Nordisk’s focus on developing innovative therapies not only for diabetes and obesity but also for associated cardiometabolic diseases such as cardiovascular disease, chronic kidney disease, and MASH.